Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival

Journal of Neuro-oncology
Signe Regner MichaelsenHans Skovgaard Poulsen

Abstract

Despite extensive treatment, overall survival (OS) for glioblastoma (GBM) remains poor. A small proportion of patients present long survival over 3 years, but the underlying molecular background separating these long-term survivors (LTS) from short-term survivors (STS) are insufficiently understood. Accordingly, study aim was to identify independent prognostic biomarkers for survival. Study cohort consisted of 93 primary GBM patients treated with radiation-, chemo- and bevacizumab therapy, among which 14 STS (OS ≤ 12 months) and 6 LTS (OS ≥ 36 months) were identified, all confirmed being IDH wild-type. RNA expression levels in diagnostic tumor specimen for 792 genes were analyzed by NanoString technology. While no differences were found with regard to GBM subtype between LTS versus STS, comparative analysis of individual genes identified 14 significantly differently expressed candidate genes. Univariate analysis in the whole patient cohort found that 12 of these were significantly associated with OS, of which increased IFNG, CXCL9, LGALS4, CD34 and decreased MGMT levels remained significant associated with prolonged OS in multivariate analysis correcting for known prognostic variables. Validation analyses in an independent data...Continue Reading

References

Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Nov 7, 2008·Journal of Cell Science·Julie S Nielsen, Kelly M McNagny
Feb 24, 2010·Clinical Neuropathology·M Galloway
Apr 20, 2010·Cancer Cell·Houtan NoushmehrUNKNOWN Cancer Genome Atlas Research Network
Jul 30, 2010·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Benedikte HasselbalchUlrik Lassen
Feb 19, 2013·Journal of Neuro-oncology·Shi-Yong WangChang-Chen Hu
May 25, 2013·Asia-Pacific Journal of Clinical Oncology·Kathryn Maree FieldKate Drummond
Aug 2, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hong-Bin ChengZhi Wang
Aug 7, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian HartmannUNKNOWN German Glioma Network
Oct 15, 2013·Cell·Cameron W BrennanUNKNOWN TCGA Research Network
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Mar 26, 2014·Neuro-oncology·Naamit K GerberTimothy A Chan
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas SandmannCarlos Bais
Sep 12, 2015·Acta Neurologica Scandinavica·B FeketeB Rydenhag
Feb 18, 2016·Journal of Neuropathology and Experimental Neurology·Lasse S KristensenHelle Broholm
Aug 20, 2016·Journal of Neuropathology and Experimental Neurology·Matthew D WoodJoanna J Phillips
Dec 10, 2016·Neuro-oncology·Sen PengMichael E Berens
Jan 25, 2017·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Nobuhiro HataKoji Iihara
Nov 16, 2017·The New England Journal of Medicine·Wolfgang WickMartin J van den Bent

❮ Previous
Next ❯

Citations

Oct 22, 2019·Journal of Cellular Biochemistry·Ying YangWen Sun
Dec 4, 2019·Oncology Letters·Jing XueWei Zhang
Sep 22, 2020·Journal of Neuropathology and Experimental Neurology·Timothy E RichardsonJamie M Walker
Feb 5, 2021·World Neurosurgery·Venkatesh S MadhugiriA Sathia Prabhu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.